
NMRA Stock Forecast & Price Target
NMRA Analyst Ratings
Bulls say
Neumora Therapeutics Inc. is positioned for significant growth within the biopharmaceutical industry, with projected U.S. sales reaching $250 million by 2030 and $950 million by 2035, aligning with consensus expectations. The company's broad pipeline, which includes key assets like NMRA-511 and navacaprant, showcases its innovative approach to treating neuropsychiatric disorders, with navacaprant expected to generate sales potential of $750 million by 2028 and peak sales of $3 billion. Recent updates highlight NMRA-511's potential to outperform current standard treatment options, underscoring Neumora's commitment to addressing underserved areas in brain disease therapeutics.
Bears say
Neumora Therapeutics Inc. reported a significant net loss of $59.5 million for the fourth quarter of 2025, raising concerns about its financial sustainability, particularly given its high research and development expenses amounting to $44.7 million. The overhang from adverse event findings in the NMRA-215 tox study has intensified investor skepticism regarding the program's viability and added risks of potential setbacks in multiple ongoing clinical trials. Moreover, the company faces future financing challenges as it must navigate the pressures of generating cash flow and possible market fundraising before achieving any cash flow positive status.
This aggregate rating is based on analysts' research of Neumora Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
NMRA Analyst Forecast & Price Prediction
Start investing in NMRA
Order type
Buy in
Order amount
Est. shares
0 shares